This review provides a comprehensive overview of the preclinical mechanisms and clinical challenges of anthracycline-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Highlights ongoing monitoring challenges in anthracycline-treated patients; leaves open optimal prevention strategies for prospective trials.
Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.
No takes yet. Share an insight, caveat, or question.
Gianni et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: